Dr. Salwa Elgebaly is the Founder and Chief Executive Officer at Nour Heart, Inc., and she currently holds an Adjunct Professor position at the Department of Surgery, University of Connecticut Faculty of Medicine, Farmington, Connecticut, USA, as well as a Visiting Professor position at the University of Alexandria Faculty of Pharmacy, Alexandria, Egypt. Dr. Salwa Elgebaly is a former Associate Professor and Director of Surgical Research Center at Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Dr. Elgebaly has been recognized by Marquis Who’s Who Top Executives for dedication, achievements, and leadership in cardiovascular health.
▪ Nobel Prize Winner in Medicine, Professor Sir John Vane, London, United Kingdom.
▪ Nobel Prize Winner in Medicine, Professor R. Levi Montalcini, Rome, Italy.
▪ Professor Sir Dr. Magdy Yacoub in London, United Kingdom.
Prof. Dr. Salwa Elgebaly is the Inventor of nine (9) Patents Issued by the U.S. Patent Office and two pending applications.
Nour Heart, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cyclocreatine Phosphate for the prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation (DRU-2015-4951).